MK-677 (Ibutamoren) vs Liraglutide

A detailed comparison to help you understand the differences and choose the right peptide for your research goals.

MK-677 (Ibutamoren)

MK-677, also known as Ibutamoren, is an orally active growth hormone secretagogue. Unlike peptides, it can be taken orally and has a long half-life, providing 24-hour GH elevation.

Full details →

Liraglutide

Liraglutide is a GLP-1 receptor agonist FDA-approved as Victoza for type 2 diabetes and Saxenda for chronic weight management. It was one of the first daily GLP-1 agonists and paved the way for newer weekly options like semaglutide.

Full details →

Side-by-Side Comparison

AspectMK-677 (Ibutamoren)Liraglutide
MechanismActs as a potent, selective agonist of the ghrelin receptor (GHS-R1a). Increases GH and IGF-1 levels without affecting cortisol. Mimics ghrelin's GH-releasing effects.Binds to and activates GLP-1 receptors, stimulating insulin secretion in a glucose-dependent manner, suppressing glucagon release, slowing gastric emptying, and reducing appetite through central nervous system effects.
Typical DosageTypical dosing: 10-25mg taken orally once daily. Often taken at night due to sleep benefits and appetite increase.Saxenda (weight loss): Start 0.6mg daily, increase weekly by 0.6mg to maintenance dose of 3mg daily. Victoza (diabetes): 0.6mg to 1.8mg daily.
AdministrationOral administration (capsule or liquid). Can be taken with or without food. Long half-life allows once-daily dosing.Subcutaneous injection once daily at any time, independent of meals. Rotate injection sites. Can be used with oral diabetes medications.
Side EffectsIncreased appetite and water retention are most common. May cause lethargy, vivid dreams, and mild numbness. Can affect blood glucose and insulin sensitivity.Nausea, vomiting, diarrhea, constipation, headache, decreased appetite. GI effects typically diminish over time with continued use.
Best For

What They Have in Common

Both MK-677 (Ibutamoren) and Liraglutide are commonly used for:

Key Differences

Ready to Learn More?